United States-based Nexus Pharmaceuticals has launched its Arsenic Trioxide Injection in 10mg per 10mL vial in the United States, following its approval by the Food & Drug Administration (FDA), it was reported on Friday.

The product is indicated for induction of remission and consolidation in patients with Acute Promyelocytic Leukaemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterised by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Nexus Pharmaceuticals chief commercial officer Omair Ahmed, said, 'The approval of generic Arsenic Trioxide injection continues to show Nexus's commitment in providing access to affordable critical-need generic injectables. Collectively, as drug manufacturers and healthcare providers, we have a commitment to patients to ensure they are receiving affordable drugs they need, when they need them, which is why we make it our highest priority to be a reliable partner in supplying critical need drugs.'